RecruitingPhase 3NCT07272434

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 60 Aears and Above

Sponsor

MAXVAX Biotechnology Limited Liability Company

Enrollment

25,000 participants

Start Date

Oct 22, 2025

Study Type

INTERVENTIONAL

Conditions

Respiratory Syncytial Virus (RSV)

Summary

This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.

Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Placebo (Saline solution) and a biological treatment called Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) for people with respiratory syncytial virus (rsv). The study is currently recruiting participants at 8 locations. People eligible for this study include aged 60 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALRecombinant Respiratory Syncytial Virus Vaccine (CHO Cell)

0.5 mL per dose

BIOLOGICALPlacebo (Saline solution)

0.5 mL per dose

Locations(8)

Guangdong Provincial Center for Disease Control and Prevention

Guangzhou, Guangdong, China

Hebei Provincial Center for Disease Control and Prevention

Shijiazhuang, Hebei, China

Henan Center for Disease Control and Prevention

Zhengzhou, Henan, China

Hubei Provincial Center for Disease Control and Prevention

Wuhan, Hubei, China

Hunan Provincial Center for Disease Control and Prevention

Changsha, Hunan, China

Shaanxi Provincial Center for Disease Control and Prevention

Xi'an, Shaanxi, China

Shandong Province Centers for Disease Control and Prevention

Jinan, Shandong, China

Sichuan Center for Disease Control and Prevention

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07272434

Related Trials

Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

NCT068518066 locations

A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

NCT074826578 locations

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

NCT075433805 locations

Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age

NCT075164186 locations

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

NCT073589101 location